Nebulized furosemide in infants with bronchopulmonary dysplasia

J Pediatr. 1994 Dec;125(6 Pt 1):976-9. doi: 10.1016/s0022-3476(05)82018-9.

Abstract

The effects of 0.1 mg, 0.25 mg, 0.50 mg, and 1.0 mg of nebulized furosemide per kilogram of body weight on pulmonary functions were studied in eight preterm infants with bronchopulmonary dysplasia who were supported by mechanical ventilation. Doses of 1 mg/kg significantly improved lung compliance (51% at 2 hours after nebulization), pulmonary resistance (28% at 1 hour), and tidal volume (43% at 1 hour), starting as early as 30 minutes after the dose; the effect lasted for at least 4 hours in many of the infants and was not associated with diuresis or renal side effects.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Airway Resistance / drug effects
  • Body Weight
  • Bronchopulmonary Dysplasia / drug therapy*
  • Bronchopulmonary Dysplasia / physiopathology
  • Bronchopulmonary Dysplasia / urine
  • Dose-Response Relationship, Drug
  • Female
  • Furosemide / pharmacology
  • Furosemide / therapeutic use*
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature, Diseases / drug therapy*
  • Infant, Premature, Diseases / physiopathology
  • Infant, Premature, Diseases / urine
  • Lung Compliance / drug effects
  • Male
  • Nebulizers and Vaporizers
  • Respiration, Artificial*
  • Respiratory Function Tests
  • Tidal Volume / drug effects
  • Time Factors
  • Treatment Outcome

Substances

  • Furosemide